Dialysis modalities and dyslipidemia

被引:65
作者
Attman, PO [1 ]
Samuelsson, O
Johansson, AC
Moberly, JB
Alaupovic, P
机构
[1] Sahlgrenska Univ Hosp, Dept Nephrol, SE-41345 Gothenburg, Sweden
[2] Sanleyo Pharma Dev, Edison, NJ USA
[3] Oklahoma Med Res Fdn, Lipoprot Lab, Oklahoma City, OK 73104 USA
关键词
hemodialysis; peritonealdialysis; lipoproteins;
D O I
10.1046/j.1523-1755.63.s84.3.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Progressive renal failure is accompanied by dyslipidemia, which is reflected in an abnormal apolipoprotein profile. It is characterized by increased concentrations of intact and partially metabolized triglyceride-rich apoB-containing lipoproteins. They occur preferentially in very-low density lipoprotein (VLDL) and low-density lipoprotein (LDL) as a result of impaired metabolism and clearance. Hemodialysis can moderately attenuate the renal dyslipidemia. In contrast, peritoneal dialysis is associated with further aggravation, including an increase of cholesterol-rich apoB-containing lipoproteins.
引用
收藏
页码:S110 / S112
页数:3
相关论文
共 20 条
  • [1] APOLIPOPROTEIN COMPOSITION AS THE BASIS FOR CLASSIFYING PLASMA-LIPOPROTEINS - CHARACTERIZATION OF APOA-CONTAINING AND APO-B-CONTAINING LIPOPROTEIN FAMILIES
    ALAUPOVIC, P
    [J]. PROGRESS IN LIPID RESEARCH, 1991, 30 (2-3) : 105 - 138
  • [2] Attman PO, 1996, NEPHROL DIAL TRANSPL, V11, P63
  • [3] LIPOPROTEIN METABOLISM AND RENAL-FAILURE
    ATTMAN, PO
    SAMUELSSON, O
    ALAUPOVIC, P
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (06) : 573 - 592
  • [4] Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis
    Attman, POA
    Samuelsson, OG
    Moberly, J
    Johansson, AC
    Ljungman, S
    Weiss, LG
    Knight-Gibson, C
    Alaupovic, P
    [J]. KIDNEY INTERNATIONAL, 1999, 55 (04) : 1536 - 1542
  • [5] Bredie SJH, 2001, PERITON DIALYSIS INT, V21, P275
  • [6] Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
    Chertow, GM
    Burke, SK
    Raggi, P
    [J]. KIDNEY INTERNATIONAL, 2002, 62 (01) : 245 - 252
  • [7] EFFECTS OF 3 TREATMENT MODES ON PLASMA-LIPIDS AND LIPOPROTEINS IN UREMIC PATIENTS
    HORKKO, S
    HUTTUNEN, K
    LAARA, E
    KERVINEN, K
    KESANIEMI, YA
    [J]. ANNALS OF MEDICINE, 1994, 26 (04) : 271 - 282
  • [8] Randomized trial of high-flux vs low-flux haemodialysis:: effects on homocysteine and lipids
    House, AA
    Wells, GA
    Donnelly, JG
    Nadler, SP
    Hébert, PC
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (07) : 1029 - 1034
  • [9] Johansson AC, 2000, PERITON DIALYSIS INT, V20, P306
  • [10] KINETICS OF PERITONEAL PROTEIN LOSS DURING CAPD .2. LIPOPROTEIN LEAKAGE AND ITS IMPACT ON PLASMA-LIPID LEVELS
    KAGAN, A
    BARKHAYIM, Y
    SCHAFER, Z
    FAINARU, M
    [J]. KIDNEY INTERNATIONAL, 1990, 37 (03) : 980 - 990